CSI Market
Sign In | Register

Foamix Pharmaceuticals Ltd (FOMX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access FOMX Annual Cash Flow →
From Foamix Pharmaceuticals Ltd through Dec 31 2018, changes in Dec 31 2019's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2019)
12 Months 		(Sep 30 2019) (Jun 30 2019) (Mar 31 2019) (Dec 31 2018)
Operating Activities
Income-95.18
Depreciation & amortization0.35
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.72
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories1.36
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property-0.02
Share-based Compensation0.06
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Income taxes23.09
Marketable Securities, Unrealized Gain (Loss), Excluding Other than Temporary Impairments, Total0.36
Increase (Decrease) in Accounts and Other Receivables-0.37
Increase (Decrease) in Accounts Payable and Accrued Liabilities18.05
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.13
Other Noncash Income (Expense)-0.14
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-73.39
Investing Activities
Capital Expenditures1.06
Sale of Capital Items0.02
Proceeds from Sale and Maturity of Marketable Securities49.82
Payments to Acquire Marketable Securities18.95
Real Estate Investments0.00
Payments Related To Amounts Funded In Respect Of Employee Rights Upon Retirement-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments26.01
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities41.87
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.37
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.03
Other net-28.16
Proceeds From Issuance Of Preferred Shares And Warrants-
Debt Conversion Converted Instrument Amount-
Conversion Of Stock Amount Converted-
Conversion Of Preferred Warrants To Ordinary Share Warrants-
Other Significant Noncash Transaction Value Of Consideration Received0.01
Proceeds From Issuance Of Convertible Loans Together With Ordinary Shares-
Cash Cash Equivalents And Restricted Cash At Carrying Value-
Cash Cash Equivalents And Short Term Investments-
Capital Expenditures Incurred But Not Yet Paid-
Cashless Exercise Of Warrant And Restricted Stock Units-
Proceeds From Issuance Of Ordinary Shares Through Securities Purchase Agreement Net Of Issuance Costs13.71
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents28.12
Proceeds From Debt Financing And Issuance Of Warrants Net Of Issuance Costs14.20
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities47.95
Effect of exchange rate on cash flow0.04
Discontinued operations0.00
Free Cash Flow-72.32
Total Cash Flow16.43
4 historic quarters locked

Sign in to unlock the full Foamix Pharmaceuticals Ltd cash flow history.

Sign In Create Free Account

About FOMX Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.